Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Fate Therapeutics Inc (NASDAQ:FATE)

4.59
Delayed Data
As of Apr 28
 -0.10 / -2.13%
Today’s Change
1.47
Today|||52-Week Range
5.68
+82.87%
Year-to-Date
No recent news for Fate Therapeutics Inc.

Today’s Trading

Previous close4.69
Today’s open4.68
Day’s range4.54 - 4.72
Volume213,117
Average volume (3 months)312,281
Market cap$190.0M
Dividend yield--
Data as of 4:00pm ET, 04/28/2017

Growth & Valuation

Earnings growth (last year)+11.02%
Earnings growth (this year)+20.00%
Earnings growth (next 5 years)--
Revenue growth (last year)+81.08%
P/E ratioNM
Price/Sales18.11
Price/Book2.60

Competitors

 Today’s
change
Today’s
% change
ENZYEnzymotec Ltd-0.25-2.82%
GNCAGenocea Biosciences ...+0.14+2.24%
ASTAsterias Biotherapeu...-0.15-3.90%
VBIVVBI Vaccines Inc+0.01+0.22%
Data as of 4:05pm ET, 04/28/2017

Financials

Next reporting dateMay 16, 2017
EPS forecast (this quarter)-$0.20
Annual revenue (last year)$4.4M
Annual profit (last year)-$33.5M
Net profit margin-760.15%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
J. Scott Wolchko
Chief Scientific Officer
Daniel D. Shoemaker
Corporate headquarters
San Diego, California

Forecasts